ISCT Webinar: Thinking Beyond Efficacy - 4 Key Considerations for Achieving Commercial Success for Cell Therapies
The Importance of Manufacturability, Costs, Reimbursement & Needle-to-Needle Logistics
Sponsored by Invetech
Date: Wednesday, December 9, 2015
- Mike Paglia, Senior Director, Technical Operations, Bluebird Bio, USA
- Mark Curtis, Business Development Analyst, Center for Commercialization of Regenerative Medicine (CCRM), Canada
- Richard Grant, Global Vice President, Cell Therapy, Invetech, Australia
- Brian Hanrahan, Program Manager, Cell Therapy, Invetech, USA
About the Webinar:
Efficacy is often the primary (and in some cases, sole) focus of most cell therapy companies. Without it, there is no therapy. However, as companies progress toward commercial manufacture with potential game changers (e.g., cures for cancer and diabetes), it is critical to think beyond efficacy, and consider the other 4 core attributes required to achieve commercial success. These key considerations include: manufacturability, cost of goods, reimbursement, and needle-to-needle logistics. During this webinar, we will discuss the importance each of these elements play in achieving commercial success, as well as key considerations and steps you must take to move cell therapies from the clinic to commercial-scale production.
Manufacturability. Key considerations for error-proofing the product manufacturing process to reduce variability and ensure consistency, reproducibility and reliability.
Cost of Goods. Ways to optimize the manufacturing process, equipment and facility to minimize costs while still maintaining product quality.
Reimbursement. New ways of looking at the reimbursement landscape.
Needle-to-needle logistics. Exploring how the variability of the entire process—from sample collection through administration—can impact product quality, and ultimately efficacy.
Registration for this Webinar has been sponsored by Invetech. The views and content expressed in this Webinar have been provided by Invetech and may not reflect the independent views of ISCT or an objective review of the products and services discussed.